ImpriMed offers personalized medicine services to help you diagnose and treat canine lymphoma or leukemia. We offer 4 levels of service:
PARR Sensitivity for B-Cell is 90.71% and for T-Cell is 85.45%.
Current therapy will not affect our AI predictions or immunoprofile results. However, reduction of tumor size caused by therapy may increase the likelihood of service failure due to insufficient cells. In the event of service failure, you will not be billed.
Yes, we do run assays on blood for a leukemia patient. Please send us at least 2 mL of whole blood in an EDTA tube.
Please contact sales@imprimedicine.com to request pricing information. We will get back to you within 1 business day.
PARR, which stands for PCR for Antigen Receptor Rearrangements, is used to discriminate between lymphoma/leukemia and reactive/inflammatory conditions when cytology is equivocal. Our canine PARR assay detects the expansion of B-cell cancer clones by amplifying the VJ region of the immunoglobulin heavy chain gene (IgH) and detects the expansion of T-cell cancer clones by amplifying a region in the T-cell receptor gamma chain gene.